Illumina illegally monopolised DNA sequencing market, rival says
Illumina obtained monopoly power over the market for next-generation DNA sequencing by concealing information from the US Patent and Trademark Office (USPTO) and through sham patent litigation, a rival company has alleged.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10